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ABSTRACT 
Alekhya Yechoor 
Determining the Fatty Acid Substrate Preferences of Long-Chain Acyl-CoA Synthetase Isoforms 
(Under direction of Rosalind A. Coleman) 
Before a fatty acid can be used in a cell, it must first be converted to its active form acyl-
coenzyme A (acyl-CoA).   This activation is catalyzed by a group of enzymes known as acyl-
CoA synthetases, which use the energy of ATP to add a CoA group to the fatty acid to create 
fatty acyl-CoA. By controlling the synthesis of fatty acyl-CoAs, long-chain acyl-CoA 
synthetases (ACSL) can regulate fatty acid uptake and metabolism by selective activation of 
fatty acids. Activated fatty acids can be channeled to numerous downstream pathways after their 
conversion into acyl-CoA.  The control over this fatty acid channeling towards different 
downstream pathways is not clear, but may vary depending on the isoform of the ACSL enzyme 
used to synthesize the acyl-CoA. Five different isoforms of ACSL (1,3,4,5,6) exist, each with 
varying roles in the body
5
.  With each isoform, there is likely to be a distinct fatty acid 
preference and metabolic fate for the generated fatty acyl-CoA
8,9,10,11
.  We expect each ACSL 
isoform to have differing chain-length and saturation preferences for its substrates. To better 
understand the substrate preferences of each isoform we used engineered expression vectors 
containing genes for each ACSL isoform along with a FLAG tag to produce purified 
recombinant enzyme. These expression vectors were transformed into E. coli and induced with 
IPTG to make recombinant protein.  The FLAG-ACSL enzyme produced was affinity purified 
using a FLAG column and then used in an indirect spectrophotometric assay with different 
substrates to determine ACSL isoform substrate preference. The specific activity for each 
isoform was calculated with fatty acids of varying chain-length and saturation, to give 
quantitative values for the preferences of each isoform. Through troubleshooting and developing 
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a protocol, we found that active isoforms were produced when induced at 25˚C for 16 hours. An 
indirect assay performed with purified ACSL5 showed activity with oleic acid and palmitic acid. 
ACSL5 showed a greater preference for palmitic acid, particularly at lower concentrations of 
purified protein.  Due to time constrictions, and problems obtaining active ACSL isoforms, the 
protocol developed will have to be used in further studies to determine the substrate preferences 
of each ACSL isoform.  
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CHAPTER 1 
INTRODUCTION 
1.1 Lipid Metabolism 
Lipid metabolism involves the synthesis, transport, and degradation of lipids.  One class 
of lipids is fatty acids, which are carboxylic acids with a long hydrocarbon chain.  Various types 
of fatty acids exist, and their properties can vary depending on chain length and degree of 
unsaturation.  Depending on these properties, fatty acids play numerous roles in the body.  Fatty 
acid derivatives are used as hormones and intracellular messengers; they are used to synthesize 
phospholipids and glycerolipids, and perhaps most significantly, they provide a crucial source of 
fuel for the body
1
.    
Most fatty acids can be synthesized in the body, but some, such as linoleic acid and 
alpha-linolenic acid, must be obtained from the diet.  These fatty acids are usually stored in 
adipose tissue as triacylglycerols, which are glycerols with three uncharged esters.  
Triacylglycerols are a highly concentrated source of fuel as they are the storage form of fatty 
acids
1
.  Fats are energy dense as they can provide 9 kcals/g, while proteins and carbohydrates can 
provide only 4kcals/g.  However, to be used fatty acids must be mobilized from triacylglycerols, 
which can be hydrolyzed within fat cells by lipases. The lipases that degrade triacylglycerol 
(TAG) are adipose triglyceride lipase (ATGL), the cAMP-regulated lipase hormone-sensitive 
lipase (HSL), and monoacylglyceride lipase (MAG lipase).  These lipases are activated through a 
second messenger cascade, and hydrolyze triacylglycerols into glycerol and free fatty acids.  
Glycerol can be converted into pyruvate, which enters the Krebs cycle to produce energy, or be 
transported to the liver for use in gluconeogenesis.  Free fatty acids released from adipose tissue 
travel to the liver and can oxidized and used to fuel gluconeogenesis or packaged into very-low 
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density lipoproteins (VLDL). They can subsequently be delivered to cells for use in cellular 
structure and function
1
. Before a fatty acid can be used in a cell, it must first be converted to its 
active form acyl-CoA.   This conversion is done by acyl-CoA synthetase, which uses the energy 
of ATP to add a CoA group to the fatty acid.   
1.2 Acyl-CoA Synthetase 
Long-chain acyl-CoA synthetase is an enzyme that converts a fatty acid of 16-22 carbons in 
length into an acyl-CoA product. This reaction is catalyzed in a two-step process involving ATP:  
1) Fatty acid+ATP acyl-AMP+PPi   2)Acyl-AMP+CoA   Acyl-CoA+AMP 
The reaction including structures is shown in Figure 1. 
 
Figure 1: Reaction catalyzed by Acyl-CoA synthetase
2
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As shown in Figure 1, the enzyme first attaches ATP to the negatively charged fatty acid. This 
creates an acyl-ATP intermediate. Then, pyrophosphate is released leaving acyl-AMP. This 
reaction provides the energy to create the high energy thioester linkage in the next step of the 
reaction.  The acyl-CoA synthetase creates a thioester linkage between the CoA and the acyl-
AMP. The AMP is then released and yields the final acyl-CoA product
3
. This fatty acyl-CoA 
product is considered ‘activated’ because the complex Coenzyme A group, rather than the 
carboxyl group in the ‘unactivated’ fatty acid, preserves the high energy potential for 
esterification. The structure for the Coenzyme A group is shown in Figure 2.  
  
Figure 2: Coenzyme A Structure
3
 
 By regulating the synthesis of acyl-CoA, long-chain acyl-CoA synthetases (ACSL) play 
significant roles in the body. Of its many roles, one of the major functions of ACSL is fatty acid 
channeling
4
. ACSL can regulate fatty acid uptake and metabolism of fatty acids by selective 
activation. The fatty acids can be channeled to numerous downstream pathways after their 
conversion into acyl-CoA. Some activated fatty acids are substrates for beta-oxidation and can be 
metabolized to acetyl-CoA.  Acyl-CoA can also be used for the synthesis of complex lipids like 
phospholipids, cholesterol esters, and triacylglycerol
5
. The control over this fatty acid channeling 
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toward different pathways is not very clear, but it may vary depending on the isoform of the 
ACSL enzyme used to synthesize the acyl-CoA
4
.  
 Five different Acsl genes are present in mammals, each encoding a different isoform of 
ACSL. These isoforms are: ACSL-1, -3, -4, -5, -6. Though encoded by different genes, each of 
the ACSL isoforms converts long-chain fatty acids to acyl-CoA. Each isoform has different 
spliced variants that differ in the 5′-UTR regions, the first encoding exon, alternative coding-
exons, and two exchangeable motifs located near the ATP-binding site
6
. These variations of the 
isoforms can create slight differences in structure that cause the distribution in cell to vary. For 
example, all ACSL isoforms except ACSL1 encode variants that produce different N-termini. 
These differences in N-termini can cause variations in how the enzyme interacts with the plasma 
membrane and subcellular membranes
6
. ACSL isoforms are thought to be mainly membrane 
proteins, however some have been detected in the cytosol of cells
7
. Research is ongoing to 
determine the actual cellular localization of ACSL isoforms.  
 Apart from difference in cellular localization, each of these isoforms can also vary in 
distribution in the body. For example, Acsl4 mRNA expression is highest in the adrenal gland 
and other steroidogenic organs, Acsl6 mRNA is most abundant in brain and skeletal muscle, and 
Acsl5 is expressed most abundantly in small intestine
7
.  This mRNA data may not directly 
correspond to protein expression; differences in expression throughout the body can be indicative 
of differences in functions in the body
4
.   
 The different ACSL isoforms also have differing substrate preferences. The activity of 
each of the different isoforms varies with their lipid environment. In experiments performed by 
the Yamamato group on purified ACSL isoforms, each isoform has different fatty acid substrate 
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preference depending upon chain length and degree of saturation. For example, ACSL1 exhibited 
highest activity with palmitic acid, palmitoleic acid, oleic acid or linoleic acid as a substrate
8
. 
ACSL3 exhibited highest activity with myristic acid, arachidonic acid or eicosapentaenoic acid 
as substrate
9
. ACSL4 exhibited highest activity with arachidonic acid, or eicosapentaenoic acid 
as substrate
10
. ACSL5 had the highest activity with palmitic acid, palmitoleic acid, oleic acid, 
linoleic acid or α-linoleic acid as substrate11. ACSL6 had the highest activity with palmitic acid, 
palmitoleic acid, arachidonic acid or eicosapentaenoic acid as substrate
8
. Though the studies 
conducted in the Yamamoto lab are often used as references for substrate preference, some 
limitations in the studies make the results obtained inaccurate. For example, the purification 
process to obtain ACSL may not have been sufficient to produce purified ACSL. Therefore, the 
results obtained regarding substrate preferences may not accurately reflect the preference of each 
ACSL isoform due to the presence of other proteins. In addition, the differences in activity were 
all measured relative to activity with palmitate, so rather than specific activity, relative activity 
was measured. Relative activity may not be sufficient to quantify or qualify the substrate 
preferences of each ACSL isoform. 
Yamamoto’s studies have been repeated by other labs.  However, numerous experiments 
conducted have all shown great variability, because with each sample preparation and procedure, 
the results for substrate specificity vary
6
. Therefore, the results obtained thus far for enzyme 
kinetics of the different ACSL isoforms may not reflect real kinetics of the enzyme
6.  
An indirect 
ACS assay ensures a sensitive measurement of the kinetics of the ACSL isoforms with different 
fatty acid substrates.  The reactions conducted in an indirect ACS assay are shown in Figure 3.  
The purpose of using this series of reactions is to couple the production of AMP formation 
produced in the ACSL reaction, with the production of NAD
+
. Change in NADH can be 
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measured at an absorbance of 334 nm and stoichiometry can be used to calculate the activity of 
ACSL.  
 
Figure 3: Reaction schematic for indirect ACS assay 
 Obtaining accurate data for substrate preference of the different ACSL isoforms is 
challenging, due to the difficulty of mimicking a cellular environment. However, determining 
substrate preference can suggest the function of each enzyme. Since ACSL plays a key role in 
lipid metabolism by converting long-chain fatty acids to their activated form, understanding the 
function of the enzyme can be useful when the mechanisms by which inflammation pathways, 
and disorders such as diabetes, occur can be better understood
12
.  
1.3 Eicosanoids 
Eicosanoids are of particular interest when determining the substrate preferences of each 
ACSL isoform. ACSL may play a modulating role in the shuttling of arachidonic acid and other 
polyunsaturated fatty acids (PUFAs) into eicosanoid synthesis. Studies conducted on the ACSL 
isoforms suggest that each isoform directs fatty acids towards or away from specific pathways. 
One of the isoforms may play a larger role in pushing fatty acid molecules towards eicosanoid 
synthesis.  ACSL4 in particular seems to push arachidonic acid toward eicosanoid synthesis
13
. A 
study done using INS 832/13 cells showed that diminished ACSL4 activity leads to increased 
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levels of free EETs and reduced esterified EETs, indicating that that ACSL4 in this model 
normally shuttles EETs towards incorporation into glycerophospholipids
13
. Since arachidonic 
acid is the primary precursor for eicosanoids, determining which isoforms have high specific 
activity with arachidonic acid, the regulation of synthesis of eicosanoids can be better 
understood. In addition, ACSL may play a role in activating lipid metabolites, such as 
eicosanoids, allowing for their incorporation into phospholipids
13
.   
Eicosanoids are a class of signaling molecules derived from ω3 and ω6 polyunsaturated 
fatty acids. The term encompasses several different compounds, including prostaglandins, 
leukotrienes, and thromboxanes
14
. They play significant roles in the body, by acting as local 
hormones and participating in intracellular signaling cascades
15
. They ensure gastric integrity, 
maintain renal function, regulate smooth muscle contraction, and control blood vessel 
contractility
16
. Eicosanoids are critical in inflammation and immunity, and researching 
eicosanoid synthesis and function is important for understanding multiple disease processes, 
including diabetes and cardiovascular disease.  
Biosynthesis of eicosanoids occurs in all cells except erythrocytes. Eicosanoids are 
synthesized from PUFAs that are derived from either linoleic or alpha-linolenic fatty acid. The 
most common fatty acid used for the synthesis of eicosanoids is the 20 carbon fatty acid 
arachidonic acid (C20:4ω6), which is derived from linoleic acid. Other common fatty acids used 
to synthesize eicosanoids are eicosapentaenoic acid (C20:5ω3), and dihomo-gamma-linolenic 
acid (C20:3ω6)13. Figure 4 shows how these fatty acids are formed.  
15 
 
 
Figure 4: omega-6 series and omega-3 series of polyunsaturated fatty acids
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The eicosanoids formed depend on the type of fatty acid used for synthesis.  Based on the 
type of fatty acid present in the diet, different or even opposing effects on bodily functions can 
be produced, as different eicosanoids will be synthesized. The biosynthesis of eicosanoids is 
controlled, as they are only synthesized when required. When a stimulus, such as trauma, or 
cytokine signaling occurs, phospholipase A2 translocates to the cell membrane, where it cleaves 
the 20-carbon fatty acid from the sn-2 position of a phospholipid
14
.  Another mechanism 
involves the cleavage of a fatty acid from diacylglycerol by diacylglycerol lipase
15
.  Once the 20-
carbon fatty acid is released, it can be converted into an eicosanoid through different pathways. 
To discuss the different pathways of eicosanoid synthesis, arachidonate will be used as 
the example, as it is the most common precursor for eicosanoid biosynthesis. The two major 
pathways for eicosanoid synthesis are the lipoxygenase (LOX) pathway, and the cyclooxygenase 
pathway (COX). Another pathway is the cytochrome p450 pathway, which produces 
hydroxyeicosatetraenoic acids (HETES) and epoxyeicosatrienoic acids (EETs).  Figure 5 below 
shows a summary of the various pathways.  
16 
 
 
Figure 5: Eicosanoid biosynthesis pathways using arachidonic acid, and sample structures
16
 
 The lipoxygenase pathway produces leukotrienes, which are important mediators of 
inflammation pathways.  For the synthesis of leukotrienes, the fatty acid, in this case arachidonic 
acid, binds to 5-lipoxygenase-activating protein (FLAP). FLAP enables arachidonic acid to 
interact with 5-lipoxygenase. The enzyme 5-lipoxygenase then converts arachidonate into 5-
hydroperoxyeicosatetraenoic acid (5-HPETE). 5-HPETE is converted into leukotriene-A4, which 
can be further converted into other leukotrienes
15
. Other lipoxygenase enzymes can transform 
fatty acids into other HPETEs and further into hydroxyeicosatetraenoic acids (HETES), or 
lipoxins. Once synthesized, leukotrienes can bind to G-protein coupled leukotriene receptors, and 
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to peroxisome proliferator-activated receptors (PPARs) to produce responses, like neutrophil 
migration and bronchoconstriction
18
.  
 The cyclooxygenase pathway converts arachidonate into either thromboxanes or 
prostaglandins. The enzyme prostaglandin H2 synthase, which has cyclooxygenase and 
peroxidase activities, utilizes arachidonate to produce prostaglandin H2. Two forms of this COX 
enzyme are present in humans: COX-1 and COX-2. COX-1 is responsible for basal levels of 
prostaglandins and is expressed in gastric mucosa, kidney, platelets, and vascular endothelial 
cells. COX-2 is activated in response to inflammation, and increases prostaglandin production 
primarily in monocytes and macrophages
19
. The final product of the reaction is prostaglandin H2. 
This molecule can be transformed into thromboxane A2 in platelets, and is prothrombotic
20
. 
Prostaglandin H2 can also be converted into prostaglandins, which usually act via G-protein 
coupled receptors. Prostaglandins can also bind to PPARs to affect nuclear transcription of 
proteins
19
. Prostaglandins have varying effects, such as contraction of smooth muscle tissue, and 
inhibition of platelet aggregation that depend on the type of prostaglandin formed, and the 
receptors on the target tissue.  
Another major pathway that synthesizes eicosanoids is the cytochrome P450 pathway, 
which produces epoxyeicosatrienoic acids (EETs) and hydroxyeicosatrienoic acids(HETEs) from 
arachidonic acid. Unlike the other pathways, this pathway is specific for arachidonic acid. Two 
separate types of enzymes exist within this pathway
17. ω-hydroxylases convert arachidonic acid 
to HETEs, while cytochrome p450 (CYP) epoxygenases produce EETs from arachidonic acid. 
The mechanism of action of HETEs and EETs is not completely understood, but like the other 
eicosanoids, they act on a G-protein coupled receptor or on PPARs.  
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While many types of HETEs can be synthesized, the primary metabolite of the ω-
hydroxylase pathway is 20-HETE, which is synthesized in the vascular smooth muscle cells
15
. 
20-HETE plays an essential role in inflammation, as it is pro-inflammatory and stimulates the 
production of cytokines in endothelial cells. It also promotes angiogenesis by controlling cell 
proliferation, migration, and survival in endothelial cells
17
. HETEs are also important 
vasoconstrictors. In contrast, EETs, which are also regulators of blood vessel diameter, are 
generally vasodilators.  EETs are synthesized in endothelial cells, as well as in hepatocytes, 
cardiac myocytes and other cell types expressing CYP epoxygenase
17
. Once synthesized, EETs 
are rapidly metabolized by soluble epoxide hydroxylase (sEH) into dihydroxyeicosatrienoic 
acids (DHETs), which are inactive. EETs can also be incorporated into phospholipids, and 
undergo beta-oxidation and chain elongation
17
.  The functions of EETs are not completely 
understood, but they seem to inhibit apoptosis, encourage cell proliferation and promote 
angiogenesis
21
.  Pancreatic physiology also seems to be affected by EETs, as increasing 
exogenous EETs can reduce glucose-stimulated insulin secretion, and alter beta-cell function, 
though this is not fully understood
13
.  
 Many different eicosanoid molecules can be produced via the three major pathways. 
Within the each pathway, the different classes of molecules synthesized can produce varying 
physiological responses. The roles of eicosanoids are further diversified depending on whether 
they have been synthesized with arachidonic acid or eicosapentaenoic acid (EPA) as the 
precursor. For example, the use of EPA instead of arachidonic produces thromboxane A3 
(TXA3), which is weaker than the TXA2 produced from arachidonate. Therefore, using EPA may 
channel synthesis of eicosanoids toward thromboxanes, which reduce platelet aggregation.  The 
differences caused by using EPA instead of arachidonic acid for eicosanoid biosynthesis are 
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summarized in Figure 6. Understanding the effects of lipid availability on eicosanoid production 
is therefore critical, as the type of lipid used for eicosanoid synthesis can result in very different 
physiological responses. 
Figure 6: The effects of using ω-3 polyunsaturated fatty acids as precursors for eicosanoid 
synthesis
14
 
Once released, eicosanoids can induce changes that vary depending on the receptors 
available on target cells
21
. Eicosanoids can target cells, bind to a receptor either on the surface of 
a cell (usually G-protein coupled receptor), or to a transcription factor (like PPAR-gamma), to 
cause cellular and physiological responses. Depending on the receptor, a variety of effects are 
produced, based on the downstream pathways activated, or proteins synthesized
21
. Figure 7 
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shows some of the functions of some important eicosanoids, as well as pathways that are targeted 
by drugs. Overall, eicosanoids play many roles in the body in nearly every organ system.  
 
Figure 7: Functions of selected eicosanoids and drugs that target the eicosanoid synthesis 
pathway
22
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CHAPTER 2 
SPECIFIC AIMS AND HYPOTHESIS 
Specific Aim One: To obtain purified FLAG-ACSL for all rat ACSL isoforms. 
Specific Aim Two: To determine the different substrate preferences of each ACSL isoform. 
Hypothesis: Each ACSL isoform will have differing chain-length and saturation preferences for 
its substrates.  
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CHAPTER 3 
METHODS 
3.1 Transformation of pFLAG-CTC-ACSL Plasmids 
Recombinant plasmids of rat pFLAG-CTC-ACSL1, –ACSL3, –ACSL4, –ACSL5 and ACSL-6 
were engineered previously E. coli strain DH5-α was transformed by taking 100 μL of competent 
cells and mixing with 5 μL of plasmid pFLAG-CTC-ACSL DNA. The cells were incubated on 
ice for 30 minutes then heat shocked at 37˚C for 2 minutes. The cells were then returned to ice 
for 1 minute. Cells were inoculated into 200 μL of Super Optimal broth with 20 mM glucose 
(SOC media) and shaken at 37˚C for 1 hour. Cultures were then plated on Luria-Bertani (LB) 
agar plates supplemented with 50 μg/mL ampicillin and X-Gal  and grown overnight at 37˚C.  
3.2 Miniprep and Sequencing of pFLAG-CTC-ACSL Plasmids 
Ampicillin colonies were selectively picked from each plate and grown in 2 mL LB broth 
supplemented with 50 μg/mL ampicillin (LB-Amp) overnight at 37˚C in a shaking incubator. 
Plasmid DNA was harvested from the cultures using the Qiagen QIAprep Spin Miniprep Kit 
using the manufacturer’s protocol was followed and 700 ng of plasmid DNA from each sample 
was sent to the UNC-CH Genome Analysis Facility to confirm that the plasmids contained the 
proper FLAG-ACSL inserts.  
3.3 Recombinant Protein Induction 
Clones containing the confirmed sequences were streaked on individual LB-Amp (50 μg/mL) 
agar plates and grown overnight at 37˚C. Two individual colonies were picked from each plate 
and placed in individual Falcon tubes containing 5 mL LB-Amp (50 μg/mL) and grown 
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overnight at 37˚C in a shaking incubator. Primary cultures were then subcultured into 500 mL 
LB medium with 50 μg/mL ampicillin and grown in a 37˚C shaking incubator23. The absorbance 
(OD600) was measured hourly for each subculture until the OD600 was approximately 0.7. Then 
cultures were transferred into 250 mL centrifuge bottles and centrifuged for 15 minutes at 5,000 
rpm at 4˚C in a Sorvall ST 16R rotor23.   
The pellets were resuspended in 500 mL Terrific Broth medium with 50 μg/mL ampicillin and 1 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The bacteria was induced at 25˚C for 16 
hours, or until the final absorbance was approximately 2.  Once this absorbance was reached, the 
cultures were again pelleted for 15 minutes at 5,000 rpm at 4˚C.  
3.4 Lysis of Bacterial Pellets  
Pellets were resuspended in 10 mL/g pellet cold breaking buffer containing 50 mM 
HEPES/NaOH, pH 7.4, 0.5 M NaCl, 5% glycerol,  0.05% n-dodecyl β-D-maltoside (DDM),  
0.05% N,N-Dimethyldodecylamide-N-oxide (LDAO), 1 mM phenylmethanesulfonyl fluoride 
(PMSF),  1 mM ATP, 5 mM MgCl2, a protease inhibitor tablet (Roche), and 10 mg/mL lysozyme 
stock from Sigma (final concentration of 0.2 mg/mL of lysis buffer) . The resuspended samples 
were incubated on ice for 30 minutes. The cells were lysed using a cell disruptor sonicator (Heat 
Systems Ultrasonics, Farmingdale, NY) at setting 3. The cells were lysed on ice for six 10 
second intervals with a 10 second break between each sonication. The lysed samples were 
centrifuged for 20 minutes at 4000 rpm at 4˚C. Aliquots of these cell extract samples were saved 
in -80 ˚C and used for conduct Western blottings.  
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3.4 Western Blot 
Protein was quantified from the cell extract samples using the Thermoscientific Pierce BCA 
Protein Assay kit. To visualize protein expression, 100 μg of protein from each of the cell 
extracts were resolved on an 8% SDS-PAGE gel at 100V for 1.5 hours. Resolved proteins were 
transferred onto a nitrocellulose membrane at 120V for 1 hour. To ensure transfer, protein bands 
were visualized with Ponceau S. The membrane was blocked in 5% non-fat dairy milk for one 
hour and then incubated for one hour with monoclonal mouse anti-FLAG primary antibody in 
the blocking solution (Sigma, dilution 1:5000). The membrane was washed with TBS-Tween 
(0.05% v/v) and incubated for 45 minutes with goat anti-mouse horseradish peroxidase 
secondary antibody (dilution 1:10000). This membrane was washed again with TBS-Tween 
(0.05% v/v) and placed on ECL substrate from Thermoscientific Pierce for 5 minutes. 
Chemiluminescence was detected by exposure to film for 1 minute.  
3.5 Separation of Membrane and Soluble Proteins 
A sucrose gradient was prepared to separate the soluble and membrane fractions of ACSL 
recombinant protein. In disposable Beckman Ultracentrifuge tubes, 0.5 mL of 5% w/v sucrose 
solution was layered on top of 2 mL 55% w/v sucrose solution. The cell extract was carefully 
layered on top of these sucrose solutions. The prepared samples were subjected to 
ultracentrifugation using an SW41 rotor at 35,000 rpm for 3 hours at 4˚C. A syringe with a 18 g 
needle was then used to collect the membrane fractions, which settled between the 5% sucrose 
solution and 55% sucrose solution. The soluble fractions were also collected. Aliquots of the 
soluble and membrane fractions were used to conduct Western blots and ACS specific activity 
assays.  
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3.6 ACS Specific Activity Assay 
Activity of the FLAG-ACSL proteins obtained were quantified (nmol fatty acid/mg protein/min) 
using [
14
C] palmitate. This assay was conducted to quickly check for activity of the proteins 
before purification. A reaction mix (contained 290 mM Tris pH 7.4, 13 mM MgCl2, 8.3 mM 
DTT, 17 mM ATP, 0.5 mM CoA, 5μM [14C] palmitate in 0.5 mM Triton X-100 in EDTA)with 
amounts of Medium 1(10 mM Tris pH 7.4, 1 mM EDTA, 0.25 M sucrose, 1 mM DTT), so that 
once protein was added the volume of protein and Medium 1 would equal 80 μL. Protein 
amounts of 20μg, 40μg, or 60μg were added to start the reaction. A positive control of total 
particulate from mouse liver was also used to compare specific activities.   
The 10-minute reactions were conducted at room temperature, and stopped with 1 mL Dole’s 
reagent (isopropanol:heptane:1 M H2SO4, 80:20:2, by volume). The unesterified fatty acid was 
removed with two washes with 2 mL heptane and 0.5mL distilled water. This mix was 
centrifuged at 1500 rpm for 5 minutes to improve phase separation. The organic phase was 
discarded and radioactivity was quantified in 600 μL of the aqueous phase by liquid scintillation 
using Ecolite. All specific activity assays used a positive control of wild-type liver total 
particulate from mouse, which was obtained by Dr. Eric Klett on 7/11/05.  
3.7 Affinity Column Chromatography 
Positively charged anti-FLAG culture beads were obtained from Sigma, and 1 mL of the resin 
was added to the column. The column chromatography was performed at 4˚C . The resin was 
washed with TBS and then activated with three column volumes of 0.1M glycine-HCL, pH 3.5. 
The column was re-equilibrated with five washes with TBS pH 7.4.  
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The cell extract samples used for purification were prepared by adding an equal volume of 
1xTBS, 1% (w/v) Triton X-100 and incubating on ice for 20 minutes. The samples were 
centrifuged at 2700 rpm for 5 minutes at 4˚C to remove DNA and debris that could clog the 
column.  
The sample was run through the prepared column three times and the final flow-through was 
stored.  The column was then washed twice with two column volumes of 1xTBS to remove 
unbound proteins. To elute the FLAG proteins, 5 mL of 100 μg/mLsolution of FLAG peptide 
(Sigma) was prepared from a 5 mg/mL stock solution of FLAG peptide and 50mM Tris-HCl pH 
7.4. For fraction 1a, 0.5mL of FLAG peptide was added and the protein collected. This was 
repeated for fraction 1b. For fractions 2-5, 1 mL of FLAG peptide was added and the fractions 
collected. These fractions were aliquoted and used for Western blots and specific activity assays 
that were done as previously described. They will also be used for an indirect spectrophotometric 
assay using NADH.  
3.8 Indirect ACS Assay 
An indirect ACS assay was used to sensitively measure the activity of each ACSL isoform with 
various substrates. In the spectrophotometric assay, the activity of ACSL was measured by 
coupling the reaction of ACSL with the reactions of adenylate kinase, pyruvate kinase and 
lactate dehydrogenase and following the oxidation of NADH at 334nm with a recording 
spectrophotometer (Beckman DU640). The reaction mix contained 100 mmol Tris-HCl buffer 
pH 8.0, 10 mmol ATP, 15 mmol MgC12, 5 mmol dithiothreitol, 150 mM KCl, 1.0 mM potassium 
phosphoenol pyruvate, distilled water, 250 μmol fatty acid (stock of 2.5 mM fatty acid dissolved 
in 15 mM Triton X-100 0.1 mM EDTA),  and 0.3 mM NADH dissolved in 100 mM 
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triethanolamine pH 8.2. An NADH standard curve was first constructed for use in calculations of 
ACSL activity using NADH concentrations of 0 M, 0.01128 M, 0.0564 M, 0.1128 M, and 
0.2256 M. Absorbance was measured at 334 nm at room temperature.  
For the reactions using purified ACSL, 45 μg adenylate kinase, 30 μg pyruvate kinase, 30 μg 
lactate dehydrogenase were added for a total reaction volume of 1 ml
24
. Varying amounts of 
purified ACSL was used to create a protein dependence curve. The reaction mix was incubated 
for 1 min at 37˚C, and the reaction was initiated by the addition of CoA (final concentration 600 
μM CoA). Change in absorbance at 334 nm was measured every 10 seconds for 3 minutes. The 
reaction rate was calculated using the slope and intercept created from an NADH standard curve.  
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CHAPTER 4 
RESULTS 
4.1 Discovering Problems with ACSL Purification 
To obtain purified protein for use in the indirect ACS assay, I originally used a protocol by 
Caviglia, Li and others
22
.  Protein expression of FLAG-ACSL4 in the rat LS2226 strain was 
measured before purification, and after separating the membrane and soluble fractions with the 
sucrose gradient.  In Figure 8A, the expected band at 75 kDa (actual size is 7440 kDa) was 
visible in the membrane and soluble fractions. Expression was also measured in each fraction 
after column purification. Fraction 1a is the first 0.5 mL of eluate after the addition of FLAG 
peptide. Fraction 1b is the next 0.5 mL, and fractions 2-5 are sequential 1 mL fractions of eluate. 
After column purification, as shown in Figure 8B, much fainter bands were visible at 75 kDa in 
membrane fractions 1b, and 2, and in soluble fractions 1b, 2 and 3, indicating protein loss during 
purification.   
     A 
 
      B 
 
 
Figure 8: Protein expression of FLAG-ACSL4 from LS2226 strain in unpurified (A) and 
purified (B) membrane and soluble fractions  
Membrane Soluble 
Membrane Soluble 
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The indirect ACS assay was performed using 0.5 mg of protein from both membrane fraction 1b 
and soluble fraction 1b with arachidonic acid as substrate. However, as seen in Figure 9A, the 
results were not as expected; instead of declining progressively, absorbance remained fairly 
constant for both soluble and membrane fractions, indicating low activity. To confirm, a 
radioactive specific activity assay was performed with palmitate as substrate. As shown in Figure 
9B, activity compared to the positive control of mouse liver total particulate was low. Though 
the activity was low, the presence of activity with the radioactive ACS assay indicates that there 
may have been some problem with the indirect assay, such as oxidation of the arachidonate.  
A 
 
 
 
 
 
B     
 
 
 
Figure 9: Low activity of FLAG-ACSL4 as shown by the indirect ACS assay (A) and 
radioactive specific activity assay using total particulate from mouse liver as positive control (B) 
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4.2 Determining Source of Problems with ACSL Activity  
To determine where the loss of enzyme activity occurred, activity of bacterial lysates was 
measured, instead of that of purified samples. The activity of the protein produced by bacteria 
containing the ACSL4 plasmid was compared to that containing an empty vector. Two clones 
were selected for each strain. In Figure 10, the results show that activity of the ACSL4 lysate 
was not different from that of the empty vector, and was much lower than that of the total 
particulate from mouse liver positive control, meaning the protein was inactive.  
 
 
 
 
 
 
 
Figure 10: Negligible specific activity of ACSL4 and EV lysates with palmitate compared to 
positive control of total particulate from mouse liver  
To further determine the source of the problem, different lysis buffers were used. The Sigma Cell 
Lytic B buffer (40 mM Tris-HCl, pH 8.0 and unspecified zwitterionic detergents), 10mM Tris 
1mM EDTA buffer, and 200mM HEPES and 1mM EDTA buffer were all tested as lysis buffers, 
but none showed improvement in specific activity (results not shown). A shorter induction of 4 
hour was used instead of an overnight induction, but this also showed no change in specific 
activity, meaning the problem was with the production of active protein.  
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4.3 Activity with New Protocol   
To resolve the problems with activity, the sequences of each FLAG-ACSL plasmid were 
confirmed and transformed into the DH5-α strain of E. coli. Upon the advice of Concetta 
DiRusso (University of Nebraska), we tried an overnight induction at 25˚C instead of 37˚C and 
the lysis buffer mentioned in the methods section was used. A radioactive specific activity assay 
was conducted with palmitate as substrate to check for activity. In Figure 11A, the activity of 
both the ACSL3 lysate and extract using the new protocol was comparable to that of the positive 
control of total particulate from mouse liver. In Figure 11B, the cell extracts of each ACSL 
isoform were used to measure specific activity. Compared to the positive control of mouse liver 
total particulate, the specific activity of the protein formed using the new protocol was high. 
ACSL4, and ACSL6 were particularly high, as they were higher than the positive control. As 
seen in Figure 11C and Figure 11D, ACSL5 had activity, and with increasing protein 
concentrations showed increased activity, as expected.  This result means that with the new 
protocol, the recombinant protein produced was active.  
A  
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Figure 11: Specific activity of ACSL isoforms with palmitate (A) Specific activity of ACSL 3 
lysate and extract compared to total particulate from mouse liver positive control (B) Specific 
activity of ACSL 1, -4, -6 extracts compared to total particulate from mouse liver (C) Specific 
activity of ACSL5 (D) Protein dependent  specific activity of ACSL 5 
The membrane fraction of FLAG-ACSL5 was purified in the affinity chromatography column 
and fractions were collected. Protein expression in the lysate, column flow through, and purified 
fractions was measured using a Western blot with an anti-FLAG antibody. Fraction 1a is the first 
0.5 mL of eluate after the addition of FLAG peptide. Fraction 1b is the next 0.5 mL, and 
fractions 2-5 are sequential 1 mL fractions of eluate. In Figure 12, protein was expressed in the 
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lysate, and the flow through, fraction 1a, 2 and 3. The flow through and fraction 2 had the 
highest expression. 
 
 
Figure 12: Protein Expression for FLAG-ACSL5 lysate, column flow through, and purified 
fractions 
4.4 Indirect ACS Assay  
Since fraction 2 showed the best protein expression, it was used for the indirect ACS assay. 
Protein amounts of 0.5, 1.5, 2, 25, and 3 μg were used with oleic acid as substrate. For palmitic 
acid as substrate, protein amounts of 0, 1, 2, and 2.4 μg were used from fraction 2.  Absorbance 
was measured at 334nm for 3 minutes to measure the oxidation of NADH to NAD
+
. The initial 
and final absorbances were used to calculate the specific activity. In Figure 13A, activity 
increased linearly with increasing concentrations of protein with oleate. In figure 13B, with 
palmitate as substrate, activity increased quickly up to 1 μg of protein, after which the specific 
activity and increased much more slowly. In figure 13C, a comparison shows that with palmitate, 
1 μg of ACSL5 produced an activity of 27 nmol NAD+/min, while with oleate, more than 2.25 
μg of protein was required to reach the same level of activity. ACSL5 seems to prefer palmitate 
over oleate as substrate, particularly at lower concentrations of protein, but at higher 
concentrations, activity is similar with either substrate.  
Lys.       FlowT.     1a          1b         2         3           4        5 
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Figure 13: Protein dependent indirect ACS assay of purified FLAG-ACSL5 from Fraction 2 
(Figure 12) (A) with oleate as substrate (B) with palmitate as substrate (C) Comparison of 
activity with oleate and palmitate as substrate 
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CHAPTER 5 
DISCUSSION 
5.1 Developing Protocol for Purified Protein 
ACSL plays a key role in lipid metabolism by selectively activating fatty acids and 
channeling them towards different pathways
5
. The five ACSL isoforms present in mammals 
show differences in tissue localization, and cellular localization, which are indicative of the 
varying functions of each isoform
7
. Of particular interest are the differing substrate preferences 
of each isoform, as activity of each isoform seems to be affected by the lipid environment. By 
determining the substrate preferences of each ACSL isoform, the function of each isoform can be 
better understood.  Learning more about ACSL isoforms, their functions, and regulation can be 
useful when studying inflammatory pathways, and disorders in which lipid metabolism is 
disturbed.  
Though studies have been conducted on the substrate preferences of each ACSL isoform, 
the experimental designs used in those studies were not optimal for properly measuring enzyme 
kinetics. Studies conducted by the Yamamato group, did not use purification methods specific 
for obtaining purified ACSL, and activity measured was not specific activity, but relative 
activity
8,9,10,11
.  Therefore, the results obtained do not provide sufficient quantitative evidence to 
confirm the substrate preferences of each ACSL isoform. In addition, the activity of ACSL 
isoforms with complex lipids, such as eicosanoids has not been measured. Activation of 
eicosanoids is important in inflammation pathways, therefore determining ACSL isoform 
preferences for eicosanoids can be useful in understanding those pathways.  
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 In this study, we attempted to resolve the problems that were present in other 
experimental designs by using purified ACSL and quantitatively measuring activity through an 
indirect ACS assay.  
 The purification process proved to be extremely difficult. The protocol used by Caviglia, 
Li and others for ACSL purification was used, but proved ineffective for this experiment
22
. 
Though FLAG-ACSL protein was produced, the enzyme showed low, or no activity. After much 
trial and error, the problem was discovered. The induction procedure caused loss of enzyme 
activity, as the high temperature induction for 16 hours was perhaps creating an environment in 
which the protein could not fold properly into its active form.  In addition, the LS2226 strain 
originally used may not have been able to support the plasmid, and the protein produced may 
have been toxic and killed the cells.  Another possible explanation is the aggregation of the 
ACSL enzyme into inclusion bodies, which could have prevented the enzyme from interacting 
with the fatty acid substrate. The problem was resolved with the use of the DH5-α E. coli strain, 
a 25˚C induction temperature and a lysis buffer containing detergents, such as DDM and LDAO 
to keep proteins solubilized and maintain activity.  
This new protocol proved to be effective in producing active ACSL protein for each 
ACSL isoform. Even after purification, the ACSL5 produced remained active, though some 
protein and activity seems to have been lost throughout the purification process. This loss of 
might be avoided by loading the sample more times onto the column. Some loss of activity, 
however is, likely unavoidable.  
The purified enzyme was active when used in an indirect ACS assay with oleic acid and 
palmitic acid as substrate, providing a quantitative measurement of ACSL5 activity with 
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different concentrations of protein. Particularly at low concentrations of protein, ACSL5 seemed 
to prefer palmitic acid over oleic acid. More trials need to be conducted to confirm this result, 
but these results indicate that ACSL5 differs in activity when substrates available are changed.   
The protocol developed can be used to further assess the activity of ACSL5 and the other 
ACSL isoforms with different fatty acid substrates. Due to time constraints and the amount of 
time spent optimizing the purification protocol, the hypothesis could not be confirmed and will 
have to be explored in future studies.  
5.2 Limitations 
The protocol developed is an improvement to other studies, due to its ability to provide 
sensitive, quantitative measurements of ACSL activity. However, this purification procedure is 
not without limitations. The plasmids used for FLAG-ACSL production produce rat ACSL 
isoforms. Therefore, the results obtained regarding enzyme activity cannot necessarily be 
directly applied to humans since the amino acid sequence of rat and human ACSL5 is only 81% 
identical. In addition, an unavoidable loss of protein activity during the purification process 
occurred due to the time required to purify the protein. Though the purification was conducted at 
4˚C, some loss of activity still occurred. Therefore, when measuring enzyme activity, the results 
obtained may not reflect true enzyme activity.   
  Another limitation of this experimental design is the challenge of obtaining proper data 
for substrate preference of the different ACSL isoforms, due to the difficulty of mimicking the 
cell-environment. Using purified enzyme was important to ensure measurement of only ACSL 
activity. In a cell, ACSL activity may be affected by other interactive proteins or substances that 
were not present in the indirect ACS assay. The indirect assay also included detergents, which 
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are not present in the cellular environment.  In addition, concentrations of chemicals used in the 
indirect assay may not reflect cellular levels. For example, the 10 mmol ATP and 600 μM CoA 
were purposely in excess, so that the reaction was not limited by reactant availability.  In 
addition, the concentrations of different fatty acids can vary greatly in the body based on diet.  
For example, values provided by Mayo Clinic Laboratories provide a large range of 650-3,500 
nmol/mL for serum values of oleic acid and 1,480-3,730 nmol/mL of palmitic acid
25
. The 
concentration of 250 μmol/mL oleic acid and palmitic acid used for the indirect ACS assay are 
well above the ranges, so these may not reflect physiological values.  
5.3 Future Studies 
Due to the amount of time used to obtain purified ACSL isoforms that retained activity, 
the different substrate preferences of each ACSL isoform could not be measured. ACSL5 seems 
to show a preference for palmitic acid over oleic acid, but further trials with wider ranges of 
protein concentrations need to be conducted to confirm this preference and determine quantify 
the activity of the enzyme. Other fatty acids with varying chain-length and saturation also need 
to be tested.  
For future studies, the procedure developed in this study can be used to measure the fatty 
acid substrate preferences of each ACSL isoform. Fatty acids with varying chain-lengths and 
saturation should be used. In addition, eicosanoids should also be tested to understand substrate 
preferences with complex lipids. For each substrate used, it is important to test activity with 
concentrations as close to physiological concentrations as possible, so the cellular environment is 
somewhat replicated, but the fatty acids should remain in excess. Wide ranges of protein 
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concentrations should also be used to determine the conditions in which a certain fatty acid is 
preferred.  
 If possible, using this procedure to produce human ACSL would be useful in better 
understanding the function of different ACSL isoforms in the human body. Determining the 
substrate preferences of ACSL isoforms can contribute to a better understanding of the function 
of each ACSL isoform, and their role in lipid metabolism and disorders of lipid metabolism.   
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